Bill > S3012

This bill aims to improve pharmaceutical access, costs, and transparency in Massachusetts. Key provisions include: - Creating an office for pharmaceutical policy and analysis within the Health Policy Commission to analyze drug spending, access, and affordability trends, and assist in identifying supplemental rebates for eligible drugs. - Expanding reporting requirements and assessments for pharmaceutical manufacturers, pharmacy benefit managers, and other entities to fund the Health Policy Commission and Center for Health Information and Analysis. - Requiring the Health Policy Commission's annual cost trends hearing to examine costs, prices, and cost trends of pharmaceutical manufacturers and pharmacy benefit managers. - Mandating coverage of specific generic and brand-name drugs to treat chronic conditions like diabetes and asthma, with limits on patient cost-sharing. - Establishing a licensing and regulatory framework for pharmacy benefit managers operating in the state. The bill aims to increase transparency, promote affordability, and enhance access to critical pharmaceutical treatments for Massachusetts residents.

https://malegislature.gov/Bills/193/S3012